CME Bridge List

Immune Checkpoint Inhibitors As Part of Personalized Treatment Approaches for Patients with Melanoma
This program will explore the evolving melanoma treatment landscape, unpacking the latest data presented at ESMO and other key meetings. Through real-world clinical cases, participants will apply emerging evidence—particularly around immune checkpoint inhibitors—to personalize care based on patient- and disease-specific factors. The faculty will also highlight shared decision-making and multidisciplinary strategies to ensure coordinated, patient-centered management for individuals with advanced melanoma.
RELEASED DATE: November 21, 2025
EXPIRATION DATE: November 21, 2026

Best Practices for the Personalized Care of Patients with Melanoma: Insights on Immune Checkpoint Inhibitors
This interactive learning environment will help you visualize and apply updates in frontline management of advanced melanoma. New combinations and targets in immune checkpoint inhibitor (ICI)-based therapy are changing first-line therapy for many patients with unresectable or metastatic melanoma. This interactive audiovisual experience will reinforce your understanding of latest data from clinical trials of immunotherapy for melanoma, highlight potential adverse events associated with treatment, and illustrate the importance of patient-centered, multidisciplinary care. Join us today to explore the use of ICIs for advanced melanoma management from a new perspective.
RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026

An Innovative View: Evaluating Combination Checkpoint Inhibition Strategies in Advanced Melanoma: Considerations with Anti-LAG3 Antibodies
This online program is designed to help oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician's assistants to ensure confidence in the management of advanced melanoma. We aim to evaluate the pathophysiology of melanoma, including the rationale for use of anti-LAG3 antibodies in combination in advanced melanoma; assess the latest clinical data and clinical trial opportunities concerning the use of anti-LAG3 antibodies for combination in advanced melanoma; and recognize safety data with combination immunotherapy approaches in advanced melanoma.
RELEASED DATE: March 03, 2023
EXPIRATION DATE: March 03, 2024










